Sarah’s Journey Through CAR-T Therapy: Pre-, Peri-, and Post-Treatment Considerations with Ide-cel

This video episode examines decision-making between CAR-T therapy and novel agents in the second-line setting, scenarios for preferring alternative therapies, and treatment strategies following progression after ide-cel, emphasizing the impact of prior CAR-T therapy on subsequent choices.

EP: 1.Meet Sarah, a 55-year-old Businesswoman With Multiple Myeloma Considering CAR-T Therapy With Ide-cel

EP: 2.Clinical Decision Making in Multiple Myeloma: CAR-T in the 2nd Line Treatment Setting

EP: 3.Ide-cel vs. Cilta-cel: Tailoring CAR T in Myeloma

Now Viewing

EP: 4.Sarah’s Journey Through CAR-T Therapy: Pre-, Peri-, and Post-Treatment Considerations with Ide-cel

EP: 5.Getting to Know Robert, a 72-Year-Old Retired Teacher Facing a Myeloma Relapse and Considering CAR-T Therapy with Cilta-cel

EP: 6.Data and Expert Considerations Supporting Cilta-cel as Second-Line Treatment for Robert

EP: 7.Strategic Choices in CAR T for Myeloma: Balancing Efficacy, Safety, and BCMA vs. GPRC5D Options

Video content above is prompted by the following:

• How do you approach the decision between CAR-T therapy and other novel agents in the second-line setting?
• In which scenarios might you prefer alternative therapies over CAR-T?
• If Sarah were to progress after ide-cel therapy, what would be your next steps?
• How does prior CAR-T therapy influence subsequent treatment choices?

Recent Videos